Table 1.
Eligible NAFLD screening population.
| Characteristics | Total eligible, n(%) (N = 9888) |
|---|---|
| Age, years | |
| 9–12 | 3967 (40.1) |
| 13–18 | 5921 (59.9) |
|
| |
| Sex | |
| Male | 5465 (55.3) |
| Female | 4423 (44.7) |
|
| |
| Location | |
| Rural | 1887 (19.5) |
| Urban | 7803 (80.5) |
| Missing | 198 |
|
| |
| BMI, percentile | |
| ≥95th–<99th (obese) | 7658 (77.5) |
| ≥99th (severe obesity) | 2230 (22.6) |
|
| |
| Preexisting conditions | |
| Diabetes | 90 (0.91) |
| Hypertension | 215 (2.2) |
| Dyslipidemia | 272 (2.8) |
| Depression/Anxiety | 835 (8.4) |
| PCOS | 24 (0.24) |
|
| |
| Prior medications | |
| Antipsychotics | 272 (2.8) |
| Anxiolytics | 188 (1.9) |
| Antidepressants | 1147 (11.6) |
| Antihypertensives | 127 (1.3) |
| Antidiabetics | 62 (0.60) |
|
| |
| Prior liver panel | |
| AST and/or ALT | 1685 (17.0) |
|
| |
| Prior primary healthcare utilization, one year average | 3.99 (3.96)† |
|
| |
| Prior specialist referral | |
| Gastroenterology | 85 (0.9) |
| Endocrinology | 119 (1.2) |
| Pediatrics | 1296 (13.1) |
†Reported as mean (standard deviation); BMI, body mass index; PCOS; polycystic ovarian syndrome; AST, aspartate aminotransferase; ALT, alanine transaminase.